Advertisement
Advertisement


News

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

March 24, 2017

The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV Infected Adults and Adolescents document was published in an electronic format that could be easily updated as relevant changes in prevention and treatment recommendations occur.

The editors and subject matter experts are committed to timely changes in this document because so many health care providers, patients, and policy experts rely on this source for vital clinical information.

All changes are developed by the subject matter groups listed in the document (changes in group composition are also promptly posted). These changes are reviewed by the editors and by relevant outside reviewers before the document is altered. Major revisions within the last 6 months are as follows:


March 13, 2017

  1. Table 5 has been updated with the following key modifications:
    1. Antiretroviral drugs are removed from this table; clinicians should refer to the Adult and Adolescent Antiretroviral Treatment Guidelines' Drug Interaction section to review potential interactions and recommendations for when OI drugs are used concomitantly with certain antiretroviral drugs.
    2. Drugs used for the treatment of hepatitis C virus infection and malaria are added to this table.
  2. Table 6 has been updated with the inclusion of adverse effects associated with drugs for the treatment of hepatitis C virus infection and malaria


November 10, 2016

  1. Coccidioidomycosis: The guideline was rewritten to update recommendations for various types of coccidioidomycosis. It emphasizes that in HIV-infected persons with CD4 counts >250/µL, coccidioidomycosis can be managed in the same manner as in those without HIV infection. The triazole antifungals fluconazole and itraconazole remain the mainstays of treatment. Antiretroviral therapy in patients with coccidioidomycosis should not be delayed because of concern for immune response inflammatory syndrome.


Related Stories

Read the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF)



This article was provided by AIDSinfo. Visit the AIDSinfo website to find out more about their activities and publications.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.